Oteseconazole: A Review
Abstract
Many women are affected by vaginal fungal infections, also called yeast infections. Vulvovaginal candidiasis (VVC) is a common fungal infection caused by Candida species, predominantly Candida albicans. RVVC compromises with women’s life. It causes symptoms – such as itching, pain, dyspareunia, dysuria, and leucorrhea2-4. Oteseconazole – a novel, oral, selective fungal cytochrome P450 enzyme 51 inhibitor, designed to avoid off-target toxicities. In clinical studies to date, oteseconazole has demonstrated impressive efficacy, a positive tolerability profile and hope for a superior RVVC treatment option. Fungal infection comes in different form like –ringworm athelets foot, toenail fungus, yeast infection and jock itch. Yeast infection of vagina and tissue at opening of vagina. Antifungal is used to treat and prevent mycosis. In this article we studied about the new FDA approved drug for vaginal yeast infection.
Copyright (c) 2022 Journal of Biomedical and Pharmaceutical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Journal of Biomedical and Pharmaceutical Research by Articles is licensed under a Creative Commons Attribution 4.0 International License.